EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Metabolic reprogramming in chronic kidney disease-cardiovascular disease comorbidity: from molecular mechanisms to therapeutic strategies

Xiang-Jing Chai, Wei Gong, Wei Chen, Dong-Yu Min, Yang Wang, Le Guan

Frontiers in Pharmacology · 09.07.2026 · 17

DOI: 10.3389/fphar.2026.1801502 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.07.2026. Verfasst von Xiang-Jing Chai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Liaoning University of Traditional Chinese Medicine, Shenyang, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) and cardiovascular disease are bidirectionally linked, with metabolic reprogramming as a central pathophysiological nexus. This review examines metabolic disturbances underlying CKD–CVD comorbidity, including energy metabolism disorders, mitochondrial dysfunction, lipid and glucose dysregulation, and mineral metabolism abnormalities. The gut microbiota–metabolic axis contributes through depletion of short-chain fatty acids, accumulation of trimethylamine N-oxide, and production of uremic toxins. These changes compromise intestinal barrier integrity and sustain systemic inflammation. Downstream consequences include oxidative stress, NLRP3 inflammasome activation, cardiac and renal fibrosis, vascular calcification, and endothelial dysfunction. We critically distinguish validated interventions from speculative strategies. SGLT2 inhibitors and GLP-1 receptor agonists have established cardiorenal protection in large randomized trials, with effects extending beyond glycemic control. By contrast, gut microbiota modulation, mitochondria-targeted therapies, and several anti-inflammatory and anti-fibrotic strategies remain at the preclinical or early-phase clinical stage, and a number of mechanistically attractive interventions have failed in confirmatory trials. We also outline areas of contradictory evidence and unresolved questions. Future directions include multi-omics integration, metabolic phenotype-based stratification, and rational drug development targeting central metabolic nodes. The review provides mechanistic insights into metabolic–immune–inflammatory crosstalk in CKD–CVD and highlights priorities for translation.

Schlagwörter

Stichwörter der Autor:innen

SGLT2 inhibitorscardiovascular diseasechronic kidney diseasegut microbiotainflammationmetabolic reprogrammingmitochondrial dysfunctionuremic toxins

Autor:innen und Institutionen

  • Liaoning University of Traditional Chinese Medicine, Shenyang, China.
  • Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China.
  • Postdoctoral Research Station, China Academy of Chinese Medical Sciences, Beijing, China.

Zitieren

APA

Chai, X. J., Gong, W., Chen, W., Min, D. Y., Wang, Y., & Guan, L. (2026). Metabolic reprogramming in chronic kidney disease-cardiovascular disease comorbidity: from molecular mechanisms to therapeutic strategies. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1801502

Vancouver

Chai XJ, Gong W, Chen W, Min DY, Wang Y, Guan L. Metabolic reprogramming in chronic kidney disease-cardiovascular disease comorbidity: from molecular mechanisms to therapeutic strategies. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1801502

BibTeX
@article{Chai2026,
  author = {Chai, Xiang-Jing and Gong, Wei and Chen, Wei and Min, Dong-Yu and Wang, Yang and Guan, Le},
  title = {Metabolic reprogramming in chronic kidney disease-cardiovascular disease comorbidity: from molecular mechanisms to therapeutic strategies},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1801502}
}
Kostenlos starten →